Notable Runner: What’s Next for Pernix Therapeutics Holdings Inc After Today’s Huge Decline?

Notable Runner: What's Next for Pernix Therapeutics Holdings Inc After Today's Huge Decline?

The stock of Pernix Therapeutics Holdings Inc (NASDAQ:PTX) is a huge mover today! About 686,112 shares traded hands or 180.64% up from the average. Pernix Therapeutics Holdings Inc (NASDAQ:PTX) has declined 97.54% since March 11, 2016 and is downtrending. It has underperformed by 103.00% the S&P500.
The move comes after 5 months negative chart setup for the $270.27M company. It was reported on Oct, 14 by Barchart.com. We have $3.77 PT which if reached, will make NASDAQ:PTX worth $32.43 million less.

Analysts await Pernix Therapeutics Holdings Inc (NASDAQ:PTX) to report earnings on November, 3. They expect $-0.05 earnings per share, down 162.50% or $0.13 from last year’s $0.08 per share. After $-0.49 actual earnings per share reported by Pernix Therapeutics Holdings Inc for the previous quarter, Wall Street now forecasts -89.80% EPS growth.

Pernix Therapeutics Holdings Inc (NASDAQ:PTX) Ratings Coverage

Out of 4 analysts covering Pernix Therapeutics (NASDAQ:PTX), 1 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 25% are positive. Pernix Therapeutics has been the topic of 9 analyst reports since August 7, 2015 according to StockzIntelligence Inc. JMP Securities reinitiated the shares of PTX in a report on Wednesday, September 9 with “Market Outperform” rating. The company was downgraded on Friday, March 11 by Needham. Brean Capital maintained the shares of PTX in a report on Tuesday, February 9 with “Buy” rating. The stock of Pernix Therapeutics Holdings Inc (NASDAQ:PTX) has “Strong Buy” rating given on Friday, August 7 by Needham. The rating was maintained by Brean Capital on Friday, August 7 with “Buy”. The stock of Pernix Therapeutics Holdings Inc (NASDAQ:PTX) has “Perform” rating given on Thursday, March 17 by Oppenheimer. As per Friday, August 12, the company rating was downgraded by Brean Capital. Brean Capital maintained it with “Buy” rating and $5 target price in Friday, March 11 report.

According to Zacks Investment Research, “Pernix Therapeutics Holdings Inc., formerly known as Golf Trust of America, Inc., is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products to meet medical needs primarily in pediatrics. The Company’s product families include Aldex, Pediatex, Z-Cof, Brovex, ReZyst and QuinZyme. Its ALDEX products are indicated for the treatment of allergies and symptoms of the common cold. PEDIATEX TD is for the treatment of respiratory allergies. Z-COF 8DM is for the treatment of allergies and symptoms of the common cold. The BROVEX products are indicated for the treatment of allergies and symptoms of the common cold. REZYST IM is a chewable tablet probiotic indicated to replace active cultures that are destroyed by diet and antibiotics and to reduce symptoms associated with irritable bowel syndrome and various gastrointestinal issues. QUINZYME is a dissolve tablet for patients with depleted ubiquinone levels and for patients on statin therapy. Pernix is based in Magnolia, Texas.”

Insitutional Activity: The institutional sentiment decreased to 0.34 in Q2 2016. Its down 0.41, from 0.75 in 2016Q1. The ratio dived, as 38 funds sold all Pernix Therapeutics Holdings Inc shares owned while 21 reduced positions. 8 funds bought stakes while 12 increased positions. They now own 12.25 million shares or 66.36% less from 36.43 million shares in 2016Q1.
Acadian Asset Ltd Liability holds 198,047 shares or 0% of its portfolio. Renaissance Tech Ltd Llc accumulated 2.21M shares or 0% of the stock. Blackrock Institutional Na last reported 710,276 shares in the company. California Pub Employees Retirement System holds 0% of its portfolio in Pernix Therapeutics Holdings Inc (NASDAQ:PTX) for 22,400 shares. New York State Common Retirement Fund holds 19,800 shares or 0% of its portfolio. Balyasny Asset Mgmt Ltd Liability last reported 11,700 shares in the company. Susquehanna Intl Limited Liability Partnership owns 108,424 shares or 0% of their US portfolio. Blackrock Fund Advsr reported 7,494 shares or 0% of all its holdings. Nelson Van Denburg & Campbell Wealth Mgmt Grp Ltd Liability Co holds 700 shares or 0% of its portfolio. Highland Management Ltd Liability Corp reported 41,000 shares or 0% of all its holdings. Bridgeway Capital Management Incorporated holds 29,000 shares or 0% of its portfolio. Blackrock Advisors Ltd accumulated 0% or 7,631 shares. Savings Bank Of America De has 107,686 shares for 0% of their US portfolio. State Street reported 21,619 shares or 0% of all its holdings. Fincl Bank Of New York Mellon last reported 44,965 shares in the company.

PTX Company Profile

Pernix Therapeutics Holdings, Inc., incorporated on November 8, 1996, is a specialty pharmaceutical company. The Firm focuses on identifying, developing and commercializing differentiated products that address unmet medical needs. It focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. The Company’s products include Treximet, indicated for acute migraine; Zohydro ER (hydrocodone bitartrate) with BeadTek, an extended-release opioid agonist indicated for the management of pain severe; Silenor (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla (desvenlafaxine extended-release tablets), for major depressive disorder. The Firm promotes selected non-core branded products, such as its cough and cold products, through co-promotion arrangements with third-party sales organizations, and distributes its generic products through its subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment